Stock Comparison
LLY vs PAVM
Eli Lilly and Co vs PAVmed Inc
Who's the better investment? Let's break it down.
The Verdict
PAVM takes this one.
This one's close — only 1.3 points separating them. PAVM wins by a hair, but both deserve a closer look.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
LLY
Metric
PAVM
Market Cap
P/E Ratio
Lower may indicate better value
Price/Book
Profitability & Growth
LLY
Metric
PAVM
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
LLY
Metric
PAVM
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
LLY
PAVM
What Could Go Wrong
PAVmed Inc. faces immediate and critical financial risk with only $6.5 million in cash against quarterly operating expenses of $8.1 million as of Q1 2026. Failure to secure substantial new funding for...
Red Flags
- 🚩PAVmed Inc. consolidated cash balance of $6.5 million as of Q1 2026 vs. $8.1 million in quarterly op...
- 🚩Persistent high cash burn rate at the parent company without meaningful offsetting revenue generatio...
- 🚩High likelihood of significant future shareholder dilution for PAVmed Inc. common stock, given ongoi...
Competitive Moat
LLY
Rating
🛡️ Wide
Trend
📈 Expanding
PAVM
Rating
🛡️ None
Trend
📈 Expanding
Investment Thesis
Eli Lilly is a pharmaceutical leader with a multi-decade growth runway, primarily driven by its innovative GLP-1 franchise (Mounjaro/Zepbound) and a robust pipeline in Alzheimer's and other high-demand therapeutic areas. Its strong R&D, manufacturing scale, and expanding market share position it for sustained, above-average growth within the healthcare sector, making it a core holding for long-ter...
Full LLY AnalysisIf PAVmed Inc. successfully secures near-term financing for its parent operations (e.g., $30M+ by Q3 2026) and Lucid Diagnostics significantly accelerates EsoGuard commercialization (e.g., reaching $5M+ quarterly revenue by Q4 2026 with expanding reimbursement) alongside Veris Health achieving FDA 510(k) clearance in late 2026, then the combined entity could see its market capitalization re-rate s...
Full PAVM AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achieving a 10x return ($10 trillion+) within a 3-5 year timeframe fundamentally unrealistic. The major gr...
Full LLY AnalysisPAVmed Inc. remains an extremely speculative investment. While Lucid Diagnostics (a subsidiary) shows nascent commercial progress with $1.3M in Q1 2026 EsoGuard revenue and 3,177 tests processed, PAVmed Inc.'s consolidated financial health is critically weak. The Q1 2026 report reveals only $6.5 million in cash and equivalents against $8.1 million in quarterly operating expenses, implying a cash runway of less than one quarter. This immediate liquidity concern for the parent company, coupled wit...
Full PAVM AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.